Intra-Cellular Therapies

Youtube Subscribe

Open: 55.59 Close: 55.86 Change: 0.27

How to get information about Intra-Cellular Therapies without reading the whole internet.

The game is changing. There is a new strategy to evaluate Intra-Cellular Therapies fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Intra-Cellular Therapies are: IntraCellular, Therapies, Intra, quarter, position, stake, share, …

Concept Map

Semantic Network

Stock Summary

Intra-Cellular Therapies, Inc. focuses on the discovery, clinical development, and commercialization of small molecule drugs. The company offers CAPLYTA for schizophrenia and bipolar depression in adults. It is also developing Lumate.

Today's Summary

Intra-Cellular Therapies, Inc. raised its stake in shares of Intra Cellular Therapsies by 11.7% in the 1st quarter. JPMorgan Chase & Co. increased its stake.

Today's News

Intra-Cellular Therapies, Inc. raised its stake in shares of Intra Cellular Therapsies by 11.7% in the 1st quarter. Bank of New York Mellon Corp. acquired a new position in Intra cellarTherapies during the first quarter worth approximately $349,000. Intra-Cellular Therapies had a negative net margin of 50.40% and a negative return on equity of 28.63%. Tower Research Capital LLC TRC increased its position in shares of Intra. Intra-Cellular Therapies (ITCI) is in the Health Care sector and Pharmaceuticals industry. Novo Nordisk ( NYSE : NVO ) and Reata Pharmaceuticals ( NASDAQ : RETA) competitors include Johnson & Johnson and Novartis. JPMorgan Chase & Co. increased its stake in Intra-Cellular Therapies by 11.7% during the first quarter of this year. Bank of New York Mellon Corp also lifted its position in the company by 5.2%. Needham & Company LLC reaffirmed a “buy’s” rating and setting a target price of $73.00.

Stock Profile

"Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York."

Keywords

Are looking for the most relevant information about Intra-Cellular Therapies? Investor spend a lot of time searching for information to make investment decisions in Intra-Cellular Therapies. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Intra-Cellular Therapies are: IntraCellular, Therapies, Intra, quarter, position, stake, share, and the most common words in the summary are: therapy, intracellular, stock, cell, company, share, inc, . One of the sentences in the summary was: raised its stake in shares of Intra Cellular Therapsies by 11.7% in the 1st quarter. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapy #intracellular #stock #cell #company #share #inc.

Read more →

Youtube Subscribe

---